Symphogen A/S Advances Sym015 into Clinical Development Using Selexis SGE (Selexis Genetic Elements)

Geneva, Switzerland, 29 June 2016 – Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, announced today that Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, has progressed its Sym015 clinical candidate into a Phase 1 dose escalation trial in patients with solid tumors. Symphogen relied upon Selexis SGE® (Selexis Genetic Elements) to facilitate the rapid, stable, and cost-effective expression of Sym015, which is a multi-targeting monoclonal antibody (MAb) mixture that targets the MET receptor.

The proto-oncogene c-MET, also called MET, has been recognized as an important mediator of uncontrolled growth of solid tumors. Research has shown that driver mutations that result in activation of the MET receptor tyrosine kinase (RTK) are associated with a wide range of human malignancies including cancers of the kidney, liver, stomach, breast, and brain.

Selexis SGEs are the foundation of the SUREtechnology Platform™. SGEs are unique epigenetic DNA-based elements that control the dynamic organization of chromatin in all mammalian cells and allow for higher and more stable expression of recombinant proteins.

“We are pleased that the power of our Selexis Genetic Elements helped Symphogen efficiently produce their next-generation antibody candidate, Sym015, and move it rapidly into clinical development,” said Igor Fisch, PhD, chief executive officer and chairman of Selexis. “The goal of our proprietary technology is to help our biopharmaceutical partners advance their discovery development programs into clinical trials and, ultimately, biologics manufacturing, offering patients new and improved treatment options.”

FOR MORE INFORMATION

·      Web www.selexis.com

·      LinkedIn www.linkedin.com/company/selexis-sa

·      Twitter www.twitter.com/SelexisSA

·      Facebook www.facebook.com/SelexisSA